ORTHO EXPANDS ITS ORAL CONTRACEPTIVE LINE: INTRODUCES ORTHO-CEPT AND BRINGS EUROPE'S NO. 1 BIRTH CONTROL PILL TO THE U.S.
RARITAN, N.J., Dec. 15 /PRNewswire/ -- Ortho Pharmaceutical Corporation, the leader in women's health products, announces that Europe's most popular birth control pill will now be available in the United States under the brand name ORTHO-CEPT(TM) (desogestrel/ethinyl estradiol). The new oral contraceptive received market clearance from the U.S. Food and Drug Administration yesterday. The new oral contraceptive, which contains the progestin desogestrel (a synthetic version of the female hormone progesterone) has already been extensively used in Europe where it has become the most widely prescribed oral contraceptive since its European introduction in 1981. ORTHO-CEPT is also one of the most extensively studied low-dose oral contraceptives. ORTHO-CEPT combines the progestin (a .15 mg dose of desogestrel) with a low-dose estrogen component (a 30 mcg dose of ethinyl estradiol) to effectively inhibit ovulation and prevent pregnancy. As with other oral contraceptives, ORTHO-CEPT is approximately 99 percent effective against preventing pregnancy when taken correctly. "We recognize the need of American women for more contraceptive choices," says Robert P. O'Neil, vice president of sales and marketing for Ortho Pharmaceutical Corporation. "Their European counterparts have traditionally had a broader selection of contraceptive products, including one with desogestrel. We are pleased to be playing a significant role in making ORTHO-CEPT -- one of the newest developments in oral contraceptive technology -- and Europe's most popular Pill -- widely available in the American marketplace." Ortho Expands Contraceptive Options With the introduction of ORTHO-CEPT, Ortho expands its oral contraceptive franchise and continues its half-century of dedication to female contraceptive needs. The introduction of ORTHO-CEPT closely follows the respective October and November launches of ORTHO-CYCLEN(R) (norgestimate/ethinyl estradiol) and ORTHO TRI-CYCLEN(TM) (norgestimate/ethinyl estradiol), new oral contraceptive products containing norgestimate, the first new progestin to enter the American market in more than 20 years. "The new progestins offered by ORTHO-CEPT, ORTHO-CYCLEN and ORTHO TRI-CYCLEN signal a change in the way Ortho views oral contraceptives," adds O'Neil. "We're providing physicians and other health care providers who have trusted and prescribed our products for the women they treat with the next generation of choice in oral contraception." Ortho Oral Contraceptives and the DIALPAK(TM) Tradition Ortho Pharmaceutical Corporation markets the most comprehensive line of oral contraceptives under brand names which include ORTHO-CYCLEN(R) (norgestimate/ethinyl estradiol), ORTHO TRI-CYCLEN(TM) (norgestimate/ethinyl estradiol), ORTHO-NOVUM 7/7/7(R) (norethindrone/ethinyl estradiol), ORTHO-NOVUM 10/11(R) (norethindrone/ethinyl estradiol), ORTHO-NOVUM 1/35(R) (norethindrone/ethinyl estradiol), ORTHO-NOVUM 1/50(R) (norethindrone/mestranol), MODICON(R) (norethindrone/ethinyl estradiol), and MICRONOR(R) (norethindrone). All Ortho oral contraceptive products are packaged in the unique DIALPAK(R) Tablet Dispenser, which has been rated number one in packaging by users and nonusers of oral contraceptives. The DIALPAK is designed to help enhance patient compliance by making it easier for women to correctly follow daily dosing instructions throughout their cycles. Each day is clearly marked on the dispenser, and a dial turns in one direction only, so that only one tablet can be removed at a time. The DIALPAK is available in a 28- day or 21-day regimen. Ortho: A Leader in Contraceptives Headquartered in Raritan, N.J., Ortho Pharmaceutical has been an acknowledged leader in contraceptive technology and a committed partner in women's health care issues for more than 50 years. Since the mid- 1980s, Ortho, through its research arm, the R.W. Johnson Pharmaceutical Research Institute, has been the only major U.S. pharmaceutical company conducting significant contraceptive research and development in the United States. Serious as well as minor side effects have been reported with use of oral contraceptives. Physicians should remain alert to the earliest manifestation of any symptoms of serious disease and discontinue oral contraceptive therapy when appropriate. -0- 12/15/92 /NOTE TO EDITORS: ORTHO-CEPT prescribing information is available./ /CONTACT: Clare Castaldo of Ortho Pharmaceutical Corporation, 908-218-6116/
CO: Ortho Pharmaceutical Corporation ST: New Jersey IN: MTC SU: PDT
LR-OS -- NY008 -- 7111 12/15/92 10:40 EST
|Printer friendly Cite/link Email Feedback|
|Date:||Dec 15, 1992|
|Previous Article:||CONCORD HOLDING CORPORATION LAUNCHES THE PAINEWEBBER OFFSHORE FUNDS FOR FOREIGN INVESTORS|
|Next Article:||THE TOPPS COMPANY, INC. REPORTS THIRD QUARTER RESULTS|